Showing 31-40 of 345 grants

Title Institution Researcher Program Duration Total Award Amount
Platforms for Cross-Therapeutic Profiling and Mechanistic Studies of Immune-Modifying Therapies in Type 1 Diabetes Benaroya Research Institute at Virginia Mason Dan Campbell Cures 01-March-2026 to 28-February-2029 $1.045.621,50
Interferons and the Integrated Stress Response: Converging Pathways in β Cell Dysfunction in Type 1 Diabetes The University of Chicago Charanya Muralidharan Cures 01-March-2026 to 28-February-2029 $285.000,00
B cell-Treg interactions in immune therapy for T1D Vanderbilt University Medical Center (VUMC) Daniel Moore Cures 01-March-2026 to 28-February-2029 $660.000,00
Type I Interferons and B Cell Metabolism as Drivers of Type 1 Diabetes Trustees of Indiana University Jamie Felton Cures 01-February-2026 to 31-January-2029 $682.534,00
Controlling cytoarchitecture and function in novel stem-cell-based implants intended for T1D therapy Mayo Clinic Quinn Peterson Cures 01-February-2026 to 31-January-2028 $600.000,00
Overcoming Production Barriers to Stem Cell-Islet Therapies Through Scalable Technologies Washington University Jeffrey Millman Cures 01-March-2026 to 29-February-2028 $550.000,00
Immune-cell targeted TLR7 antagonist to halt the attack on beta−cells in the context of Type 1 Diabetes Tezcat Bio Craig Ramirez Cures 15-January-2026 to 31-December-2026 $100.000,00
Stromal Cell Targeted Tolerogenic mRNA Therapy for T1D Endotope Biosciences Raymond Liang Cures 15-December-2025 to — $550.417,82
Process development for adipose tissue implantation of immune evasive ES-derived islet-like cells University of Wisconsin-Madison (Board of Regents University of Wisconsin System) Jacques Galipeau Cures 01-January-2026 to 31-December-2027 $628.883,28
Co-engineering stem cell-derived beta cells and regulatory T cells to treat type 1 diabetes Medical University of South Carolina Leonardo Ferreira Cures 01-January-2026 to 31-December-2028 $1.049.999,80